• Edesa Biotech priced a USD 25 million underwritten public offering of common shares, pre-funded warrants, common share warrants.
• Deal includes 3,870,500 common shares with matching common share warrants, priced at USD 5.5 per share-warrant package.
• Also offers pre-funded warrants for up to 675,000 shares with matching common share warrants, priced at USD 5.4999 per package.
• Common share warrants carry a USD 7.5 exercise price, expire in 18 months or 30 days after Phase 2 EB06 vitiligo topline data.
• Underwriters received a 30-day option for 681,825 additional shares with matching common share warrants; closing expected about Aug. 21, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608192220PRIMZONEFULLFEED9813283) on August 20, 2026, and is solely responsible for the information contained therein.